Mylan to buy Agila of India for $1.6 billion

  • February 28, 2013

CANONSBURG (AP) — Generic drug maker Mylan Inc. says it will buy Agila Specialties for $1.6 billion in cash, expanding its offerings of injectable drugs and its sales in international markets.

Southpointe-based Mylan is buying Agila from Strides Arcolab. It could pay Strides another $250 million based on other undisclosed conditions. Mylan said the deal will give it new generic injectable drugs and will help it enter the market in emerging markets like Brazil.

Mylan expects the Agila purchase will add to its earnings. The transaction is expected to close in the fourth quarter.

Both Agila and Strides are based in India.

Mylan is one of the biggest generic drug companies in the world. Its sales grew 11 percent to $6.8 billion in 2012.


blog comments powered by Disqus

Orders for U.S. durable goods rise strong 3 percent in October

Applications for U.S. unemployment benefits fall to 260,000

Deere’s profit tops forecasts even as its sales fall sharply

Consumer spending up a weak 0.1 percent in October

Work begins on outdoor venue at The Meadows

Consumer confidence falls hard in November

Home prices jump in September by most in more than a year

U.S. economy grew at 2.1 percent rate in third quarter

Markets fade after an early gain, finish with small losses

Home sales slump in Oct. as higher prices weigh on buyers